SCHEMBL5057680

SCHEMBL5057680

Cc1cc(F)c(NC(=O)Nc2cnn(C(C)(C)C)c2)cc1-c1cc2cnc(NCC(O)CO)nc2n(C)c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 10/20 0.56
RAF1 P04049 6/20 0.56
ABL1 P00519 6/20 0.45
SRC P12931 4/20 0.45
MAPK14 Q16539 3/20 0.45
PDGFRB P09619 3/20 0.45
PDGFRA P16234 3/20 0.45
KIT P10721 1/20 0.45
KDR P35968 6/20 0.39
KRAS P01116 5/20 0.39
MAP2K2 P36507 3/20 0.39
MAP2K1 Q02750 3/20 0.39
FGFR1 P11362 4/20 0.38
MAPK13 O15264 1/20 0.38
FYN P06241 1/20 0.38
ARAF P10398 1/20 0.38
EPHA2 P29317 1/20 0.38
CSK P41240 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4424556 0.89 BRAF (0.58) BRAFRAF1ABL1SRCMAPK14
SCHEMBL4571003 0.89 BRAF (0.58) BRAFRAF1ABL1SRCMAPK14
SCHEMBL4571002 0.89 BRAF (0.58) BRAFRAF1ABL1SRCMAPK14
SCHEMBL5061701 0.89 ABL1 (0.47) BRAFRAF1ABL1SRCMAPK14
SCHEMBL5066945 0.88 BRAF (0.69) BRAFRAF1ABL1SRCMAPK14
SCHEMBL4563431 0.87 BRAF (0.58) BRAFRAF1ABL1SRCMAPK14
SCHEMBL5062766 0.87 BRAF (0.58) BRAFRAF1ABL1SRCMAPK14
SCHEMBL5067058 0.84 BRAF (0.57) BRAFRAF1ABL1SRCMAPK14
SCHEMBL5057581 0.83 RAF1 (0.54) BRAFRAF1SRCPDGFRBPDGFRA
SCHEMBL5067057 0.83 RAF1 (0.54) BRAFRAF1SRCPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US claimed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885ABL1 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.